Table 2

Patient characteristics
Lead author (year) Country of conduct and year Age category Mean age (SD) in years M/F, % Sample size
Vaccine Placebo
Leibovitz (1971) [24] USA, 1970 Adults NR NR 1,682 7,934
Beutner (1979) [25] USA, 1974 Children Range: 7 to 14 50/50 520 460
Rytel (1977) [26] USA, 1974 Adults NR 0/100 95 48
Monto (1982) [27] USA, 1979 Adults NR NR 144 140
Tannock (1984) [28] Australia, 1981 Adults 34.8 (13.9) 69/31 19 20
Keitel (1997) [29] USA, 1983 to 1988 Adults Range: 30 to 60 NR Y1: 161 Y1: 298
Y2: 172 Y2: 241
Y3: 153 Y3: 253
Y4: 203 Y4: 217
Y5: 121 Y5: 145
Gruber (1990) [30] USA, 1985 Children 7.9 (3.3) NR 54 77
Edwards (1994) [31] USA, 1986 to 1990 Adults/Children Range: 1 to 65 NR LAIV/TIV
Y1: 872/878 Y1: 878
Y2: 1,029/1,060 Y2: 1,064
Y3: 1,114/1,126 Y3: 1,125
Y4: 999/1,016 Y4: 1,016
Clover (1991) [32] USA, 1989 Children 8.8 (3.6) NR TIV/BIV 54/56 82
Govaert (1994) [33] The Netherlands, 1991 Older patients Range: 60 to 91 47/53 927 911
Powers (1995) [34] USA, 1993 Adults Range: 18 to 45 NR TIV/other 26/26 24
Belshe (1998) [35] USA, 1996 Children 3.5 (1.4) 47/53 1,070 532
Rudenko (2001) [36] Russia, 1996 Older patients Median: 73, Range: 41 to 95 30/70 LAIV/TIV 111/93 109
Belshe (2000) [37] USA, 1997 Children 4.5 (1.4) 52/48 917 441
Bridges (2000) [38] USA, 1997 to 1999 Adults Median: 43.5 78/22 Y1: 138 Y1: 137
Y2: 141 Y2: 137
Hoberman (2003) [39] USA, 1999 to 2001 Children Range: 0.5 to 2 56/44 Y1: 273 Y1: 138
Y2: 252 Y2: 123
Tam (2007) [40] Multisite trial in Asia, 2000 to 2002 Children 1.9 (0.6) 53/47 Y1: 1,653 Y1: 1,111
Y2: 503 Y2: 494
Vesikari (2006) [41] Multisite trial in Europe and Israel, 2000 to 2001 Children 2.0 (0.7) 51/49 Y1: 951 Y1: 665
Y2: 640 Y2: 450
Bracco Neto (2009)a[10] Multisite trial in South Africa and South America, 2001 to 2002 Children Range: 0.5 to 3 49/51 Y1: 944 Y1: 942
Y2: 338 Y2: 342
Forrest (2008) [42] Multisite in Asia, 2002 Children 1.8 Range: 0.5 to 3 NR 525 516
Lum (2010) [43] Multisite trial in Asia, Europe and South America, 2002 Children 1.2 (0.3) 50/50 765 385
Langley (2011) [44] Canada, 2003 Adults 37.1 (12.2) 46/54 455 443
Ohmit (2006)a[11] USA, 2004 Adult 26.9 (9.3) 38/62 LAIV/TIV 519/522 206
Treanor (2007)a[12] USA, 2004 Adults Median: 31, Range: 18 to 49 37/63 151 153
Beran (2009) [45] Czech Republic, 2005 Adults 35 (13) 45/55 4,137 2,066
Jackson (2010) [15] USA, 2005 Adults 32.7 (9.1) 40/60 Y1: 1,706 Y1: 1,725
Y2: 2,011 Y2: 2,043
Ohmit (2008)a[13] USA, 2005 Adults 24.9 (NR) 40/60 LAIV/TIV 853/867 338
Beran (2009) [46] Multisite trial Europe, 2006 Adults 40.0 (13.3) 40/60 5,103 2,549
Monto (2009)a[14] USA, 2007 Adults 23.3 (7.4) 38/62 LAIV/TIV 813/814 325
Frey (2010) [47] Multisite trial North America and Europe, 2007 Adults 32.5 (NR) 44/45 LAIV/TIV 3,776/3,638 3,843
Range: 18 to 48
Treanor (2011) [48] USA, 2007 Adults 32.5(NR) 41/59 2,344 2,304
Range: 18 to 55
Barrett (2011) [49] Multisite trial in USA, 2008 Children Range: 18 to 49 NR 3,619 3,617
Cowling (2010) [50] Hong Kong, 2008 Children Range: 6 to 15 53/47 71 48
Talaat (2010) [51] USA, 2009 Adults and older patients 56.5 (18.0) 43/57 389 97

aUnpublished data was obtained from the author(s).

LAIV live attenuated influenza vaccine, NR not reported, TIV trivalent inactivated vaccine.

Tricco et al.

Tricco et al. BMC Medicine 2013 11:153   doi:10.1186/1741-7015-11-153

Open Data